Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 – GlobeNewswire

Study Evaluates Combination Treatment with Investigational SHP2 and KRASG12C Inhibitors in Patients with KRASG12C Mutant Solid Tumors

REDWOOD CITY, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a Phase 1b clinical trial evaluating the combination of RMC-4630, the companys investigational SHP2 inhibitor, and AMG 510, Amgens investigational KRASG12C inhibitor. The trial, which is being sponsored and conducted by Amgen with clinical supply of RMC-4630 provided by Revolution Medicines, is an open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the combination of RMC-4630 and AMG 510 in patients with advanced solid tumors harboring the KRASG12C mutation.

RMC-4630 is a potent and orally bioavailable small molecule that is designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a central role in modulating cell survival and growth by transmitting signals from receptor tyrosine kinases to RAS. AMG 510 is a first-in-class investigational oral therapy designed to selectively and irreversibly target the KRASG12Cprotein, an oncogenic RAS mutant at the core of the RAS signaling cascade.

Preclinical and clinical research has shown that cancers caused by RAS pathway mutations exhibit oncogene addiction, in which tumor cells become highly dependent on signaling through the RAS pathway to survive. Suppressing KRASG12C activity, either directly with AMG 510 or indirectly by inhibiting SHP2 with RMC-4630, has shown anti-tumor activity against non-small cell lung tumors harboring KRASG12C in early clinical trials. In addition, adaptive resistance to inhibition of RAS signaling is common. SHP2 is an upstream RAS pathway node that often plays a key role in adaptive resistance, and inhibiting SHP2 with RMC-4630 has been shown preclinically to suppress adaptive resistance to KRASG12C inhibitors.

Our strategy is to advance a broad clinical program to assess the therapeutic potential of RMC-4630 in both monotherapy and multiple combination treatment regimens. With our recent demonstration of encouraging monotherapy activity for RMC-4630 against KRASG12C lung cancers, it is compelling to pair this investigational drug with KRASG12C inhibitors such as AMG 510, said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. This collaborative trial sponsored by Amgen, a leader in the field, will help test our hypothesis that RMC-4630 may be useful as the backbone of targeted therapy combinations for the treatment of various RAS-dependent tumors.

RMC-4630 and AMG 510 have each demonstrated activity in early-stage clinical trials in patients with KRASG12C tumors, stated Steve Kelsey, M.D., president, research and development at Revolution Medicines. Initiation of this trial is an important step in the evaluation of this combination and its potential to treat RAS-dependent cancers by simultaneously inhibiting the activity of different oncogenic targets within the RAS signaling cascade.

About RMC-4630 and Sanofi Collaboration

RMC-4630 is currently being evaluated in a Phase 1 monotherapy clinical trial (RMC-4630-01) for a range of tumor types featuring specific, molecularly-defined oncogenic mutations, a Phase 1b/2 study (RMC-4630-02) in combination with cobimetinib in patients with relapsed/refractory solid tumors displaying specific genomic mutations, and in the recently initiated Amgen-sponsored Phase 1b study in combination with AMG 510 in patients with advanced solid tumors harboring the KRASG12C mutation.

The SHP2 inhibitor program, including RMC-4630, is the focus of an exclusive global research, development and commercialization agreement with Sanofi.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company focused on developing novel targeted therapies to inhibit elusive high-value frontier cancer targets within notorious growth and survival pathways, with particular emphasis on RAS and mTOR signaling pathways. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.

The companys pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the company is developing a broad portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway and the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and SOS1, as well as RMC-5552, a development candidate within the companys 4EBP1/mTORC1 program currently in IND-enabling studies.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation statements regarding Revolution Medicines development plans and timelines, including without limitation the planned clinical study of RMC-4630 in combination with an investigational KRASG12C inhibitor, AMG 510, the potential anti-tumor mechanisms for SHP2 inhibitors, Revolution Medicines goal of assessing the therapeutic potential of RMC-4630 as monotherapy or in combination treatment regimens to treat RAS pathway cancer, and the potential benefits of, and markets for, Revolution Medicines product candidates. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Revolution Medicines programs early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Revolution Medicines ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Revolution Medicines capital resouces to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 14, 2020, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Read more:

Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 - GlobeNewswire

‘Our China boycott medicine is hitting the right spot’: Sonam Wangchuk reacts to Amul ad, Google Play Store report – Livemint

Sonam Wangchuk is happy with how his boycott China call has led to an action-oriented disruption of Chinese services in India. Reacting to the news stories about Amul account suspension, Google Play Store removal of anti-China apps and a Global Times report on Indian consumers, Wangchuck said, " This is a good news, our medicine is hitting the right spots."

"The people's call for boycott of Chinese products, uninstallation of Chinese apps is forcing China to coerce Google and Twitter to take down the anti-China narrative," Wangchuk said in a brief Youtube video uploaded Monday.

"The only takeaway from the recent China-related controversies are that people's call for action is having a far reaching impact, please continue on this path," said the man who inspired Aamir Khan's character in Bollywood blockbuster 3 idiots.

Wangchuk also pointed out a report of China's state-run publication, Global Times titled, "Indians can hardly resist buying Chinese quality goods: analysts," adding that the boycott call is impacting China, otherwise Global Times would not have commented on this.

Ladakh-based innovator and educationist Sonam Wangchuk had appealed to Indians to boycott Chinese products in the backdrop of the recent standoff between Indian and Chinese forces along the Line of Actual Control (LAC) in that region.

Wangchuk's call of "give up all Chinese software in a week, all Chinese hardware in a year," has resonated with millions of Indians in the face of Chinese aggression in the Eastern Ladakh reason.

Subscribe to newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

See more here:

'Our China boycott medicine is hitting the right spot': Sonam Wangchuk reacts to Amul ad, Google Play Store report - Livemint

From obesity to allergies, outdoor play is the best medicine for children – The Sector

What if there was a simple, inexpensive and fun way to address some of the major challenges facing humanity today. What if it could help improve childrens health, development and well-being?

Imagine a solution that could stem the current epidemics of obesity, anxiety and depression affecting children and youth today. Imagine that this solution could also promote brain health, creativity and academic achievement and prepare our children for the rapidly-changing work force.

Along the way it could reduce incidence of allergies, asthma and other immunity challenges and improve eye health. It could foster a culture of environmental stewardship and sustainability and help build the health of cities promoting neighbourliness and feelings of community connection.

Imagine that this intervention could also help countries meet their targets for many of the United Nations Sustainable Development Goals, such as the goals of Good Health and Well-being, Inclusive and Equitable Quality Education, Decent Work and Economic Growth and Climate Action.

This isnt an expensive intervention, or one that parents have to force their children to do like homework or eating their vegetables. Rather than dreading it, children report being at their happiest when doing it and they seek ways to keep at it for as long as possible.

What is this fix-all simple solution? Playing outside.

Many of us have fond memories of childhoods spent outside, hanging out with friends in our neighbourhoods, parks and wild places, making up the rules as we went along, with minimal (if any) adult supervision.

We need only reflect on our own play memories to realize how valuable these experiences can be and how they can shape our lifelong health and development. The research is now catching up to our intuitions, recognizing the vast and diverse benefits of outdoor play.

Playing outside is not the same as playing inside. There are unique benefits of being in the outdoors, particularly in nature, that dont come as readily indoors. When children are allowed to play the way they want to play in stimulating environments, they move more, sit less and play longer.

They get their hands in the dirt and are exposed to microbes that help them build their immunity. They make their own goals and figure out the steps to attain those goals, helping them build executive function skills. They learn, build resilience and develop their social skills, learn how to manage risks and keep themselves safe. Their eyes get the exercise they need to help combat short-sightedness.

We are rediscovering the magic of outdoor play. Governments see it as a way of getting kids active and averting the obesity crisis. Schools and early childhood centres see it as a way of promoting academic and socio-emotional learning. Corporations see it as a way of preparing children for the jobs of the future that will focus on creativity, empathy and connection with others. Children just see it as a way of having fun and feeling free!

There are three key ingredients to supporting outdoor play: time, space and freedom.

Kids need time to be able to play outside. In schools, that means recess policies that get kids outside every day, finding opportunities to use the outdoors for learning and limiting homework. At home, that means laying aside screens and limiting scheduled structured activities.

Kids also need high quality outdoor spaces to play in. That doesnt necessarily mean expensive playground equipment. It means spaces where all children feel welcome, regardless of their abilities and backgrounds, that they can make their own and that also have loose parts (for example sticks, stones, water and cardboard boxes) they can use and let their imagination shape the play.

In cities, that means being prepared for and allowing play to happen everywhere, not just parks and playgrounds. We need to design inclusive and child-friendly cities where kids feel welcome everywhere and can easily access nature.

Finally, freedom: the biggest barrier to childrens ability to play the way they want to play is adults. We need to let go of our excessive fears of injuries and kidnapping and realize that the benefits of kids getting out to play far outweigh the risks. My lab developed a risk reframing tool for parents and caregivers to help them on this journey.

Helping support childrens outdoor play can be as simple as opening the front door. It doesnt have to be complicated or expensive. If we all do our bit, we can help bring back this crucial activity that should be part of all childrens daily lives, regardless of age, cultural background, gender or ability.

There are lots of tools to help you get started, whether youre a parent, caregiver, educator, city planner or a neighbour.

I would encourage you to consider one simple and attainable thing you are going to do today to help get the child or children in your life get out to play.

Mariana Brussoni, Associate Professor of Pediatrics and Population and Public Health, University of British Columbia

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read the original post:

From obesity to allergies, outdoor play is the best medicine for children - The Sector

Plant drug factories: GMOs and gene editing are poised to transform medicine. Heres how. – Potato News Today

Plant biotechnology is poised to drastically improve how we consume medication. Using the modern tools of genetic engineering, researchers are developing plant-based drugs that are cheaper, easier to take and even more effective than their existing counterparts. Tautvydas Shuipys reports for the Genetic Literacy Project.

Shuipys writes that while many diseases can be treated with orally administered medications, other drugs such asbiologics or biopharmaceuticals, medicines derived from living organisms, must be delivered using other strategies. Conventional drugs like aspirin are chemically synthesized and can survive digestion, whereas biologics like hormones, antibodies, enzymes, and other complex organic molecules are vulnerable to degradation by enzymes in our saliva and stomach, as well as environmental conditions like pH and heat.

This makes biologics in pill form unlikely to survive the harsh environment of the digestive tract.

There are more than 200 FDA-approved biologic drugs. While less than two percent of people in the US rely on biologics,they make up 40 percent of prescription drug spending.

Identifying a better way to produce and administer biologics has the potential to ease the physical and financial burden associated with these drugs. For this reason, researchers are turning to the original inspiration for medications: plants.

Evidence for plant use in medicine dates back all the way to thePalaeolithic Age. But instead of trying to find new plants that produce medically relevant compounds, researchers are turning to genetic engineering to express the same biologics currently grown in bacterial, yeast, or mammalian cells.

Producing biologics in plants has anumber of advantages. Plants are potentially less costly to grow, requiring inexpensive fertilizers instead of specialized cell culture growth media. Plants can also be grown in fields or greenhouses without requiring sterile environments, meaning that scaling up production would just require more growing area as opposed to additional expensive bioreactors. An added benefit is that plants do not serve as hosts for human pathogens, reducing the likelihood of harm from contaminants that bacterial or mammalian cells may house.

In addition to medication production, companies are also looking to utilize some of the benefits of plant-based production for vaccines. Medicago, a Canada-based company seeking approval for theirplant-produced flu vaccine, has announced that using this same technology, they have produced acandidate vaccine for COVID-19in twenty days.

By growing the protein for the vaccine in plants, as opposed tousing eggs to propagate the virus, Medicago has been able to cut the cost and time required to produce a new vaccine. The vaccine is now awaiting clinical testing and FDA approval.

Read Tautvydas Shuipys full article on this topic on the Genetic Literacy Project website here.

Continued here:

Plant drug factories: GMOs and gene editing are poised to transform medicine. Heres how. - Potato News Today

University of Rochester Medicine to cut ribbon on Olean oncology infusion site June 19 – Olean Times Herald

OLEAN Officials hope to cut the ribbon at a new $1.7 million chemotherapy infusion center next month, and everyones invited.

The oncology outpatient clinic at 1504 W. State St., previously the home of Family Video, is being developed by Wellsville-based Jones Memorial Hospital part of the University of Rochester Medicine network. UR Medicine officials reported that the first patients will be seen Monday at the facility, and a virtual ribbon-cutting will be held June 19.

There are a limited number of options for celebrating an event like this, said Brenda Szabo, vice president of specialty services at Jones Memorial. We can only have 10 people attend the event in person, but wanted to make sure that everyone who is interested can see everything the new center has to offer so we will be broadcasting it as a Facebook Live event and then posting that video on our website.

Local oncologist Dr. Neeta Soni, who joined the UR Medicines Wilmot Cancer Institute team last year, will continue to provide consultation and treatment to oncology patients at The Infusion Center at Jones Memorial in Wellsville, as well as the new office in Olean.

Officials reported this winter that the network currently treats between 1,500 and 2,000 patients a year through Southern Tier Cancer Care on East Delaware Avenue. That practice opened in 2003. The new site will replace that facility, and almost double the number of infusion bays to cut wait times for patients.

We wanted to keep access to these services close to home and convenient for these communities, Szabo said. Cancer patients who were driving to larger metropolitan areas like Buffalo and Rochester, can avoid that drive and receive quality cancer care with Dr. Soni, an experienced and knowledgeable oncologist.

The project was given contingent approval by the state Department of Health on Dec. 3, with an assigned start date of Jan. 31. The original completion date was May 31, as construction efforts were well underway before the COVID-19 pandemic gripped the nation.

According to the filing with the DOH, the center will serve as a centralized point for oncology infusions chemotherapy for the hundreds of area patients.

The project also aims to help increase income for the hospital as officials attempt to leave the Vital Access Provider Program. VAP, a state program to help financially distressed healthcare entities, helps fund operational costs for turnaround initiatives with a focus on financial viability, meeting service needs, improving care quality and increasing health equity for populations at risk.

The filing states the project is expected to add a minimum of $800,000 of operating income to the hospitals annual budget. The move will also take the operation from a for-profit enterprise to a nonprofit one.

Jones Memorial joined UR Medicine in late 2015.

Excerpt from:

University of Rochester Medicine to cut ribbon on Olean oncology infusion site June 19 - Olean Times Herald

TTU School of Veterinary Medicine receives $1.4 Million CPRIT recruitment grant – KLBK | KAMC | EverythingLubbock.com

by: News Release & Posted By Staff | newsweb@everythinglubbock.com

Artist rendering of the Texas Tech University School of Veterinary Medicine in Amarillo.(Photo provided by Texas Tech University)

LUBBOCK, Texas (NEWS RELEASE) The following is a news release from Texas Tech University:

TheCancer Prevention and Research Institute of Texas(CPRIT) has awarded a transformative grant to theTexas Tech University School of Veterinary Medicine in Amarillodesigned to bring to the schools growing faculty one of the worlds leading cellular and molecular biologists.

The $1.4 million grant will allow Klementina Fon Tacer, a postdoctoral researcher at St. Jude Childrens Research Hospital in Memphis, Tennessee, since 2016, to join the veterinary school faculty. Supported by this award, Fon Tracer will investigate the novel mechanisms that protect mammalian germ cells against stress and how those mechanisms are co-opted in cancer, with the ultimate goal of advancing cancer treatment and fertility preservation of childhood cancer survivors.

The hope is Fon Tacers research will establish a strong foundation for a comparative oncology research center in the School of Veterinary Medicine.

What we do and why we do it is simple. We are here to benefit Texas and Texans, saidGuy Loneragan, dean of the School of Veterinary Medicine. Dr. Fon Tacer is going to change lives for generations to come. When we first had the chance to meet her, it was clear. Her research is transformative and will impact countless Texans in the years ahead. I am so thankful to the CPRIT Oversight Committee for awarding Texas Tech this recruitment award to make it possible to bring Dr. Fon Tacer to Texas and to the School of Veterinary Medicine. Her work in comparative oncology will save lives.

The Recruitment of First-Time, Tenure-Track Faculty Members Award, one of seven awarded by CPRIT this week and part of 13 academic research recruitment and product development awards totaling $56 million, is the first CPRIT grant awarded to the School of Veterinary Medicine, which is scheduled to open its doors to students for the first time in the fall of 2021.

Fon Tacer earned her Doctor of Veterinary Medicine (DVM) and Doctor of Philosophy in Biochemistry and Molecular Biology from the University of Ljubljana in Slovenia. She also holds a Master of Science in Biochemistry and Molecular Biology from the University of Ljubljana.

Fon Tacer is not new to Texas, having served as a postdoctoral researcher and Fulbright Fellow at the University of Texas Southwestern Medical Center in Dallas from 2006-2008. From there, she returned to the University of Ljubljana as a postdoctoral researcher and later as an adjunct assistant professor on the veterinary faculty at the University of Ljubljana until 2012.

Among her research interests at St. Jude Childrens Research Hospital are melanoma antigen genes (MAGE), very common cancer immunotherapy targets and their role in cancer reproduction, metabolism and stress response.

We are very excited to have support from CPRIT for building the faculty of our new School of Veterinary Medicine, saidJoseph Heppert, vice president of theOffice of Research & Innovation. One-health research themes developed by faculty like Dr. Tacer will have enormous benefits for both human and animal health. TheTexas Tech University Systemhas strong potential for collaboration in one-health research across the Texas Tech andTexas Tech University Health Science Centercampuses, and we are extremely proud to be adding new faculty who will capitalize on these opportunities.

Thanks to the generosity of Amarillo and communities across Texas, and the commitment of legislators from around the state, the Texas Tech University School of Veterinary Medicine in Amarillo, established in 2018, is working to enroll its first class in the fall of 2021, pending approval by the AVMA Council on Education.

The School of Veterinary Medicine will recruit and select students with a passion to practice and succeed in rural and regional communities. Its curriculum is focused on the competencies and skills necessary for success in practices that support these communities. Texas Techs innovative and cost-efficient model partners with the wider community of veterinary practices across the state to provide clinical, real-world experiential learning.

In June 2019,Gov. Greg Abbott signed into law the biennial state budget, which appropriated $17.35 million for the School of Veterinary Medicine in Amarillothat will go toward operational needs in order to get the school up and running. The appropriation included language directing Texas Tech to move forward in establishing the school.

To date, CPRIT has awarded almost $2.5 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 181 distinguished researchers, supported the establishment, expansion or relocation of 36 companies to Texas and generated more than $3 billion in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 5.7 million life-saving cancer prevention and early detection services, reaching Texans from all 254 counties. In November 2019, voters in Texas approved a constitutional amendment authorizing an additional $3 billion in bonds for cancer research and prevention.

(News release from Texas Tech University)

Here is the original post:

TTU School of Veterinary Medicine receives $1.4 Million CPRIT recruitment grant - KLBK | KAMC | EverythingLubbock.com

Office of Faculty Affairs announces faculty promotion and tenure – The South End

The Wayne State University School of Medicines Office of Faculty Affairs and Professional Development announced promotions and tenure status for more than 75 faculty members.

This year we had a record number of School of Medicine faculty members who received the well-deserved recognition of being promoted to a higher academic rank. Among these were faculty members who distinguished themselves as scientists, educators, renowned clinicians, dedicated citizens and community leaders, said Vice Dean of Faculty Affairs Basim Dubaybo, M.D. It is gratifying but not surprising that even during a debilitating pandemic, our university continues to fulfill its academic and service missions without hesitation. This reflects our commitment to our students and our community, where a large number of physicians who participate in our academic mission have received the recognition and promotion they have earned.

Five faculty were granted tenure, including Associate Professor of Oncology Asfar Azmi, Ph.D.; Associate Professor of Ophthalmology, Visual and Anatomical Sciences Elizabeth Berger, Ph.D.; Associate Professor of Physiology Robert Wessells, Ph.D.; Associate Professor of Obstetrics and Gynecology Nerissa Viola, Ph.D.; and Associate Professor of Obstetrics and Gynecology Nardhy Gomez-Lopez, Ph.D.

I am honored to receive the promotion of tenure at the Wayne State University School of Medicine. I am grateful to be part of the Perinatology Research Branch, whose translational research is dedicated to improving the lives of mothers and children, Dr. Gomez-Lopez said. This accomplishment was largely due to the successful collaborations that I have established in the intellectually-stimulating environment within the Perinatology Research Branch. I am particularly grateful to (PRB Chief and Professor of Obstetrics and Gynecology) Dr. Roberto Romero and (Professor and Chair of Obstetrics and Gynecology) Dr. Chaur-Dong Hsu for their continuous support of women in science.

A complete list of promoted faculty is now available at https://facaffairs.med.wayne.edu/ptawards

A formal celebration will be held at a later date.

See the original post:

Office of Faculty Affairs announces faculty promotion and tenure - The South End

A strange, difficult time to study medicine | Features | albanyherald.com – The Albany Herald

SAVANNAH Ally Freeman, whos pursuing her doctorate in physical therapy at Georgia Southern University in Savannah, used to spend about nine hours a week getting hands-on experience in a classroom or a lab.

That was before the COVID-19 pandemic, which has disrupted daily life around the globe as governments and private businesses try to contain the spread of the virus.

Freeman and other students working on degrees in the medical field now find themselves in a predicament they could not have anticipated. With restrictions on human interaction, they cant do some of the things they would normally be doing to gain proficiency.

Our whole curriculum depends on learning skills and being hands-on, says Freeman, 24, whose classes are now conducted entirely online. Thats whats been so hard. Because at some point, they have to make sure that we are safe to treat people.

The impact of COVID-19 has affected every industry. Clerical workers have left their office cubicles to work from home. Restaurant workers have shifted from table duty to handling curbside pick-ups. Teachers are engaging with their students online instead of in the classroom.

Like other businesses, health care educational institutions have implemented virtual classes on a temporary basis. But the move to such relatively remote learning can go only so far. Medical education, like the medical profession itself, often requires personal interaction and touching.

You cant just graduate from PA school and not have touched a patient, Bailey Dickinson, a 24-year-old physician assistant student at South University in Savannah, said.

Restrictions on human interaction have left medical education institutions trying to adjust as best they can. In March, for example, the Association of American Medical Colleges, which accredits major teaching hospitals, recommended that medical students not be involved in direct patient contact. This move was based partly on limited availability of personal protective equipment and testing, the AAMC said in mid-April.

Medical educators have taken extensive measures to modify their lessons, and theyve had to do it fast.

All the faculty hit the ground running because medical school students schedules are so constricted, Dr. Amy Baldwin, the campus director of curriculum for first- and second-year students at the University of Georgia and Augusta University medical partnership, said.

Higher education systems throughout Georgia have already gone virtual for the remainder of the spring semester. Now they are transitioning courses to be taught online in summer, too, according to the updated guidelines from the University System of Georgia. And educators hopes for a normal fall are up in the air.

In the meantime, students face an unprecedented challenge as they adjust to the new learning environment. Freeman says her current schedule consists of virtual classes in the morning, followed by videos and tasks that must be completed by the next days class.

Were trying to get everything that can be done through demonstration videos and reading. But ... thats a ton of material, Freeman said.

From a medical educators perspective, virtual Zoom meetings have been an effective tool for professors. Nothing beats in-person instruction, but faculty are doing their best to work with available technology.

Our faculty have made use of a lot of different instructional mechanisms, Baldwin said.

Students like Freeman still are concerned about how the programs will make up for lost time and build the vital skills needed for them to be confident in their future health careers.

Among students in the UGA/AU medical partnership program, the third-year students are considered to be in their clinical years, because thats when they are ordinarily in the hospitals doing their rotations or clerkships. Baldwin notes that the pandemic has been most disruptive for these students, because clinical opportunities have become scarce.

Thats the case for Dickinson, the PA student, who was about to start clinical rotations. During rotations, a student is placed in a medical specialty, like working as a physical therapist or in a family practice office, getting hands-on experience under the supervision of seasoned practitioners.

Our program used to have eight rotations, five weeks each, in different settings, Dickinson said. So we would go into a pediatrics office, into surgical units in the hospital, various places like that. We have now switched to two and a half weeks online with virtual cases, followed by two and a half weeks of clinic at places that arent hospitals.

In addition, the strain that the pandemic has put on hospitals has closed off many opportunities for students. Numerous hospitals are not taking any students at this time, and students who were matched with hospitals before the pandemic have had those rotations canceled or delayed.

Virtual case studies act as patient simulation exercises, so students can still learn to diagnose and treat specific medical conditions. For example, after observing a robotic patient on the screen, Dickinson must click the appropriate boxes to indicate which types of lab work the patient needs.

Finding ways to incorporate real-life scenarios into medical training has been an important task for Baldwin and the rest of the UGA/AU faculty.

Weve worked students who have graduated from the program into the curriculum, Baldwin said. Theyve been on the front lines for COVID-19 and have come back and given their perspective.

Some students are concerned about their ability to complete necessary steps in order to enter a medical program.

I have an entire checklist of things I need to get done before starting my program in August, Emily Gwaltney, a 25-year-old pre-nursing student at Athens Technical College, said.

The list includes updating immunizations, becoming CPR-certified, and having a standard background check and a drug screening test.

I really dont feel like Im in a place to visit anywhere to complete these tasks because, in my opinion, theyve got bigger fish to fry, Gwaltney said.

For Baldwins students, the first anatomy lab exam was conducted virtually.

Instead of in-person, hands-on, it was done with images, Baldwin says.

Students are eager to return to their normal habit of working one-on-one with patients, because thats central to what theyll be doing once they begin their careers.

There is something to be said for seeing patients in a clinic, hands-on, with the doctor that youre with, Dickinson said. I feel like youre more likely to remember the disease and the treatment if you see the case in person.

For Freeman, patient interaction is critical to being a good physical therapist.

You can watch all the videos you want, she says, but its important to actually feel whats working or not working for a patient. And without repetitive practice, so that certain tasks become second nature to the caregiver, its hard to get proper experience.

Despite the current problems, students know they will eventually get the patient interaction they need to become licensed. They cant move forward without it.

Our accreditation depends on students having a certain amount of hours in clinicals, so they cant just shorten that, Freeman said.

While the disruptions of the pandemic have delayed some important steps in receiving a medical degree, Baldwin said she is not worried that these delays will negatively affect the students future professional lives. She said she believes studying in a time of pandemic restrictions, with all the inconveniences involved, has pushed the students to be more resourceful.

I think this situation, and how our program has adapted to it, has really developed an institution and a population of learners that are much more resilient, she says.

Now, more than ever, the world needs trustworthy reportingbut good journalism isnt free.Please support us by subscribing or making a contribution today.

Andi Clements is a public relations graduate student at the University of Georgia. She received her bachelors degree in economics and is interested in business and nonprofit sustainability. She has a portfolio at https://andiclements.wixsite.com/mysite.

See the original post:

A strange, difficult time to study medicine | Features | albanyherald.com - The Albany Herald

Medicine, music and philanthropy honoured – The Bay’s News First – SunLive

Posted: 7:20am Monday 01 Jun, 2020

Traditional Maori medicine expert Robert McGowan. Image: Daniel Hines/SunLive.

Traditional Maori medicine expert Robert McGowan reckons getting recognition from the Queen could encourage more people in Tauranga to help take care of the whenua.

The Tauranga man has been recognised for services to Maori and conservation on the 2020 Queen's Birthday Honours List.

Robert has been involved with Nga Whenua Rahui since 2006, a Ministerial fund established in 1991 to provide funding for the protection of indigenous ecosystems on Mori land.

Over the past 25 years, he has worked to help restore the practice of rongoa Maori - traditional Maori medicine - in New Zealand.

Robert was a bit embarrassed when he first found out he had made it onto this years Queens Birthday Honours List.

But then, he realised it could encourage people to help protect the planet.

The recognition is a way of getting the message out there, and encouraging and involving people. But also giving them hope that we can turn things around.

A guiding principle Robert lives by is Ka ora te whenua, ka ora te tangata - When the land is well, the people will be well.

All the things we need to stay alive come out of the earth, he explains. If she is not well, then we cannot be well.

If we make looking after Papatunuku the most important thing in our lives, then we all have a much better chance of surviving the future.

Robert says indigenous medicinal plants can be used to help regenerate bush, and are good indicators for the state of the environment.

Medicinal plants are really good indicators about the state of our environment because their main job is to heal the land.

He commends environmental care groups across Tauranga and the rest of New Zealand that put the work in to look after the earth.

In Tauranga Moana, and throughout New Zealand theres hundreds of thousands of people involved in groups doing their little bit. Look at the Aongatete Forest Project.

Robert says his biggest concern is the indifferent approach some Kiwis have towards looking after the environment.

The biggest worry is lots of people are quite indifferent and dont actually stop and think about it. We have got to really try and reach those people - so they can listen and get involved.

The most important thing for me as an older person is to pass on what I know to those that follow on.

Robert was the founding Chair of the Kaimai-Mamaku Catchments Forum from 2006 to 2018 and was involved in ensuring that the Tauranga Harbour and Waihou Catchments were managed sustainably.

He was also awarded the Loder Cup in 2018 for 25 years of contribution to investigating, promoting, retaining and cherishing New Zealands indigenous flora.

Morris McFall

A Tauranga philanthropist says building a rehabilitation centre for people with disabilities is one the most important contributions to the community he has made in his lifetime.

Morris McFall has been recognised for services to the community and philanthropy on the Queen's Birthday 2020 Honours List.

Tauranga's Morris McFall has been recognised for his services to the community and philanthropy. Pictured: Morris and his wife Hilary McFall.

But rehabilitation centre Next Step Gym isnt the only cause the former Te Awamutu dairy farmer has contributed funds, time and resources towards.

The founder of the McFall Group of Companies has supplied Waipuna Hospice, Westpac Helicopter Trust, Starship Hospital and the St Johns Ambulance with much-needed resources to help improve their services.

Inspiration for establishing the Mount Maunganui gym came about after a traumatic farming accident in 2002 that left Morris son Bryce McFall tetraplegic.

Our middle son was the only farmer of the three boys and he was about to take over our dairy farm. Then he had a quad bike accident and became a tetraplegic.

We went through the process of having doubt that he would even survive.

But Bryce did survive, and Morris says part of this is thanks to the aftercare he received following the accident.

He has very considerable disabilities, but he has made a real success of his life. Our son is an example of what can eventuate of good rehabilitation and aftercare.

Morris says the facility has been a success story, and continues to give people in Tauranga with living disabilities a lot of pleasure.

I guess you would have to say that it is one of the important things we have done in life.

Next Step is for people with all forms of disabilities, particularly those with spinal injuries, post-operative care and congenital problems.

Morris and his wife Hilary McFall have also been major sponsors for Paralympics New Zealand in recent years.

He is both a Fellow and Life Member of the Chartered Institute of Logistics and Transport and was awarded the Sir Bob Owens Trophy for an outstanding contribution to the logistics supply chain, transport sector, and the community.

This is one of the most prestigious awards I have received - it is pretty special, he says.

Morris was also a Waikato Regional Councillor from 1992 to 2001 and chaired the Regional Land Transport Committee for this period.

It has been a nice surprise getting this recognition, says Morris.

I dont go to a lot of trouble seeking kudos, but I must say I have been very blessed to have a wife who has been so supportive. That has helped to no end.

Morris and Hilary have just celebrated 61 years of marriage.

The pair say they prioritise making substantial contributions to the organisations that need them most, he says.

Morris joined Te Awamutu Rotary Club in 1978 where he was a founding member of the Pirongia Forest Park Lodge.

He personally carried out all of the site development and access roading. He also constructed and installed the viewing platform for the Te Awamutu Rose Gardens as a Rotary project.

Coreen Gray

Music has brought Coreen Gray a lifetime of joy, but never in a million years did the Tauranga woman expect to receive recognition from the Queen for her choral contributions.

Coreen, who has been a singer and voluntary music teacher since the 1980s, says she is absolutely staggered to have made the Queens Birthday Honours List this year.

I just cant imagine that I have done enough to be awarded such a wonderful thing. I am just so thrilled about it, she says.

Coreen joined the Tauranga community choir Oriana Singers in 1985 and lead them until 1996 she was a member for a total of 29 years.

She also helped establish the Tauranga Womens Institute choir in 1993, of which she was choir mistress and conductor.

One of the many highlights of Coreens career was judging the young Kiri Te Kanawa at a singing competition in Te Awamutu.

She was just a young girl, and I will never forget how impressed I was with her voice.

Musical involvements continue to keep Coreen busy nowadays, with her volunteering as a singing instructor for people with dementia at Bayswater Retirement Village, as well as working with general residents to stage musical productions four times a year.

The singing teacher says music will always be a part of her life simply because she just loves it.

Every Sunday she plays the organ at St Marys Anglican Church in Mt Maunganui.

The singing teacher says music will always be a part of her life simply because it makes her happy.

I just love it. I am only so sorry that as one gets older it is just not the same as it used to be, but I still sing.

Coreen was a vocalist and accompanist with the Tauranga Civic Choir for 10 years and was made a Life Member in 2013.

She is part of Registered Music Teachers New Zealand, and a member and past conductor of the Te Puke Lyceum Choir.

Coreen reiterates that anyone can get joy from music whether that be from participating or listening.

It just one of those things that really is a joy of life. And there can be enjoyment from both participating and listening.

More here:

Medicine, music and philanthropy honoured - The Bay's News First - SunLive

Letter to the Editor: Medical cannabis is not really medicine – Press Herald

I write regarding the recent article State loses mental health grants over medical cannabis.

I have been a physician practicing Internal Medicine in Maine since 1978. I have never prescribed medical cannabis Last week The New England Journal of Medicine published an article saying there is no currently accepted medical use and a high potential for abuse for marijuana. Adequate scientific studies have not been done. Physicians cannot say that marijuana provides medical benefit or does not have harmful side effects. The name medical marijuana is a misnomer since no scientific data support its medical benefit. The statewide referendum which passed and now allows its sale was ill advised.

More scientific studies are needed to know the risks we are taking prescribing this drug. Your article explains that Maine is losing $3.3 million federal dollars used in the Maine-AWARE Program to bolster the social service infrastructure to support student mental health. You state this loss is a setback for a state that is trying to cope with an alarming amount of mental health issues among students. Maine had the highest rate in the country of children diagnosed with depression, anxiety, or attention deficit disorder.

Since the FDA considers marijuana a controlled drug, this conflicts with the Maine medical marijuana law which is allowing students to take medical marijuana in the classroom.Clearly, we are going down a harmful path. All medications, especially mind altering drugs, need careful testing before they are made available to patients, especially students.

Daniel WoodWoolwich

Invalid username/password.

Please check your email to confirm and complete your registration.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.



See the article here:

Letter to the Editor: Medical cannabis is not really medicine - Press Herald


Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Aesthetic Medicine market.

Trusted Business Insights presents an updated and Latest Study on Aesthetic Medicine Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Aesthetic Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Aesthetic Medicine Market Size, Share, Market Research and Industry Forecast Report, 2019-2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Aesthetic Medicine Market

The global aesthetic medicine market size was valued at USD 52.5 billion in 2018 and is anticipated to expand at a CAGR of 8.9% over the forecast period. Innovation in aesthetic devices in the past decade has led to growth in demand for aesthetic treatments. The introduction of technically advanced products, such as non-invasive body contouring systems using controlled cooling technology is projected to create growth opportunities for the market in near future.Moreover, the rise in disposable income has boosted the demand for cosmetic surgeries, thereby accelerating market growth. Rising population prone to experiencing signs of aging coupled with rising consciousness about physical appearance is anticipated to further drive the demand for aesthetic medicine. The trend of combination treatments in aesthetics is on a rise. Aesthetics is now being combined with lasers and radiofrequency to achieve smoother and sustained results.

Growth in population between the ages 30 and 65 years is anticipated to boot the number of target consumers with signs of aging, such as wrinkles, lack of skin elasticity and dark spots. For instance, according to the Central Intelligence Agency (CIA) World Factbook, around 39.9% of the total German population was aged between 25 to 54 years and around 15.0% of the population was aged between 55 to 65 years in 2018. This factor is anticipated to drive the demand for aesthetic medicine from the country in the forthcoming years.Moreover, the need for improved aesthetics in the rapidly rising working-class population is likely to boost the usage of aesthetic medicine over the forecast period. According to Statista, U.S. alone had a working population of 155.76 million in 2018. With improving employment rates especially in the emerging markets, the market is anticipated to witness lucrative growth over the forecast period. However, the side effects associated with aesthetic procedures are likely to continue negatively impacting the consumer preference index.ProcedureType Insights of Aesthetic Medicine Market

Non-invasive procedures segment dominated the aesthetic medicine market in 2018 and is expected to register the fastest CAGR over the forecast period. According to the 2017 Plastic Surgery Statistics Report, in U.S., around 15.7 million minimally invasive cosmetic procedures were performed during the same year, around 2% more than 2016. This highlights the rise in number of minimally invasive cosmetic procedures being performed, such as laser hair removal, microdermabrasion, and botox injections. As per a Plastic Surgery Statistics Report, botox injection is considered as the top minimally invasive cosmetic procedure with more than 7.4 million procedures performed in the U.S. in 2018. This has led to high demand for minimally invasive or non-invasive procedures, propelling the overall market growth.Invasive procedures, such as liposuction, breast augmentation, and nose reshaping, among others are some of the popular aesthetic procedures. Rise in number of men and women wanting to improve their aesthetic appearance has been fueling the demand for liposuction procedures or devices. According to a 2017 Plastic Surgery Statistics Report by the American Society of Plastic Surgeons, liposuction was among the top five cosmetic procedures in 2017 with over 246,354 procedures being performed during that year. Since 2006, breast augmentation is the top cosmetic surgical procedure according to the Plastic Surgery Statistics Report 2018.

Regional Insights of Aesthetic Medicine Market

In 2018, North America accounted for the largest market share in terms of revenue. Well-developed healthcare infrastructure, adoption of cosmetic procedures, increasing prevalence of skin disorders, and the presence of board certified and skilled cosmetic surgeons in the region are some of the major factors contributing to the growth. According to the American Society of Plastic Surgeons (ASPS), U.S. is reported to top the list of countries with the maximum number of cosmetic surgeons in the world in the year 2017. Awareness regarding aesthetic appeal and rising consciousness regarding outward appearance is also significantly contributing to the regional market growth.

Asia Pacific is anticipated to register the fastest CAGR of 10.8% over the forecast period, owing to a large number of surgical procedures performed in South Korea, Japan, and China each year. Availability of skilled professionals, advanced techniques, and cheaper treatment costs are anticipated to attract more customers. China and India have the largest population pool aged between 30 and 65 years. Moreover, rising disposable income coupled with presence of a large pool of working population is generating demand for aesthetic procedures in these countries, further fueling the regional market growth.

Market Share Insights of Aesthetic Medicine Market

The market is highly fragmented in nature with many local players competing with international players. However, strict regulatory approval process is challenging new product entries. Some of the key players contributing to the global market include Allergan, Hologic (cynosure), Johnson & Johnson, Galderma, Lumenis, Solta medical, Syneron candela, and Alma Laser.Rapid adoption of advanced devices for improved treatment, and technological advancements are the primary parameters affecting the competitive nature of the market for aesthetic medicine. In addition, the major players frequently engage in mergers and acquisitions to retain market share and to diversify the product portfolio.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Aesthetic Medicine Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, this market research report has segmented the global aesthetic medicine market report on the basis of procedure type and region:

Procedure Type Outlook (Revenue, USD Million, 2019 2030)

Invasive Procedures

Breast augmentation


Nose reshaping

Eyelid Surgery

Tummy tuck


Non-invasive Procedures

Botox injections

Soft tissue fillers

Chemical peel

Laser hair removal



Quick Read Table of Contents of this Report @ Aesthetic Medicine Market Size, Share, Market Research and Industry Forecast Report, 2019-2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more here:


2026 Projections: COVID-19 Medicine Market Report by Type, Application and Regional Outlook – Cole of Duty

The COVID-19 Medicine market report Added by Market Study Report, LLC, enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

The COVID-19 Medicine market report provides a granular assessment of the business space, while elaborating on all the segments of this business space. The document offers key insights pertaining to the market players as well as their gross earnings. Moreover, details regarding the regional scope and the competitive scenario are entailed in the study.

Request a sample Report of COVID-19 Medicine Market at:https://www.marketstudyreport.com/request-a-sample/2619180

This report studies the COVID-19 Medicine market status and outlook of global and major regions, from angles of players, countries, product types and end industries, this report analyzes the top players in global COVID-19 Medicine industry, and splits by product type and applications/end industries. This report also includes the impact of COVID-19 on the COVID-19 Medicine industry.

Emphasizing the key factors of the COVID-19 Medicine market report:

Thorough analysis of the geographical landscape of COVID-19 Medicine market:

Highlighting on the competitive landscape of COVID-19 Medicine market:

Ask for Discount on COVID-19 Medicine Market Report at:https://www.marketstudyreport.com/check-for-discount/2619180

Additional factors of COVID-19 Medicine market research report:

Research objectives:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-covid-19-medicine-market-research-report-2020

Related Reports:

1. COVID-19 Impact on Manufacturing Inventory Software Market, Global Research Reports 2020-2021Read More: https://www.marketstudyreport.com/reports/covid-19-impact-on-manufacturing-inventory-software-market-global-research-reports-2020-2021

2. COVID-19 Impact on Liquid Crystal Display (LCD) Drivers Market, Global Research Reports 2020-2021Read More: https://www.marketstudyreport.com/reports/covid-19-impact-on-liquid-crystal-display-lcd-drivers-market-global-research-reports-2020-2021

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

View post:

2026 Projections: COVID-19 Medicine Market Report by Type, Application and Regional Outlook - Cole of Duty

Preventive Medicine Market Growth Prospects and Outlook 2020-2025 – Cole of Duty

The Preventive Medicine Market report provides a comprehensive perspective of the Global market, along with a detailed analysis of the major segments and gives a forecast from 2020-2026. The Preventive Medicine Market report is a valuable source of insightful data for business strategists to make informed decisions. It provides the industry overview in terms of key parameters like growth rate, historical & futuristic cost, revenue, demand, and supply data (as applicable). The report explores the market at a global and regional level from the perspective of market size, growth rates, market drivers, key players, product types, and end-use industries. The study provides comprehensive data set in an easily accessible PDF and Excel format that enhances the understanding, scope, and application of this report for the end-user.

(Special Offer: Get Flat 20% Discount on this Report)Get a Sample Copy of this Report:https://www.marketinsightsreports.com/reports/05262043776/global-preventive-medicine-market-growth-status-and-outlook-2020-2025/inquiry?Mode=19

Top Leading Companiesof Global Preventive Medicine Market areNovo Nordisk, Eli Lilly, Preventive Medical Health Care, Cancer Prevention Pharmaceuticals, Quanterix, Phoenix Medicine, U.S. Preventive Medicine, and others.

The leading players of Preventive Medicine industry, their market share, product portfolio, company profiles are covered in this report. The leading market players are analyzed on the basis of production volume, gross margin, market value, and price structure. The competitive market scenario among Preventive Medicine players will help the industry aspirants in planning their strategies. The statistics offered in this report will be precise and useful guide to shape the business growth.

Global Preventive Medicine Market Split by Product Type and Applications:

This report segments the Global Preventive Medicine Market on the basis ofTypesare:

Public Health and General Preventive Medicine

Occupational Medicine

Military Preventive Medicine

On the basis ofApplication,the Global Preventive Medicine Market is segmented into:




Regional Analysis for Preventive Medicine Market:

For comprehensive understanding of market dynamics, the global Preventive Medicine market is analyzed across key geographies namelyUnited States, Europe, China, Japan, Southeast Asia, India, Central & South America.Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Get Discount on this report:https://www.marketinsightsreports.com/reports/05262043776/global-preventive-medicine-market-growth-status-and-outlook-2020-2025/discount?Mode=19

Table of Contents of Global Preventive Medicine Market:

Preventive Medicine Market Overview Global Preventive Medicine Market Competition, Profiles/Analysis, Strategies Global Preventive Medicine Capacity, Production, Revenue (Value) by Region (2015-2020) Global Preventive Medicine Supply (Production), Consumption, Export, Import by Region (2015-2020) Global Preventive Medicine Market Regional Highlights Industrial Chain, Sourcing Strategy and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis Market Decisions with respect to present scenario Global Preventive Medicine Market Forecast (2020-2025) Case Studies Research Findings and Conclusion

The research includes historic data from 2015 to 2020 and forecasts until 2025 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, Preventive Medicine Market report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and market development rate and figure and so on. Preventive Medicine industry report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals includingHealthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReportsprovides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:Irfan Tamboli (Head of Sales) Market Insights ReportsPhone: + 1704 266 3234 | +91-750-707-8687[emailprotected]|[emailprotected]

Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Read this article:

Preventive Medicine Market Growth Prospects and Outlook 2020-2025 - Cole of Duty

From Hollywood to the hospital, a Halifax man’s creative path to medicine – CBC.ca

Only months into the COVID-19 pandemicand Dalhousie University medicine's 2020 valedictorian, Dr. David Hung, has already produced two medical education videos to aid doctors and paramedics fighting in the trenches.

Some might consider high-quality videos about high-stakes medicine impressive.

But creating content is nothing new for this newly minted doctor who's about to start his emergency medicine residency in Halifax.

Here's the twist: for the past few years, he's trained his camera on celebritieslike Travis Scott, Kylie Jenner and Kanye Westwhom he's featured ina Netflix documentary,a shoe commercialand a music video.

Whether it's videos about viruses or rap stars, he's found the formula forsuccess. "You have a taskand you just do your best to accomplish that in really the safest possible way,"said Hung. "At the end of the day, it's all the same."

Hung's unusual path to medicine started two decades ago when he was 11. Hegrabbed his dad's VHS camera to make videos of what he loved.

"I thought I was going to grow up to be a skateboard video director, you know, at the time way before YouTube," Hung said in an interview at the Halifax Commonskateboardpark, where you'll still find him riding.

He fulfilled his early ambition byshooting and editing videos and commercials. From mini-films featuring Nova Scotia skateboarding star Johnny Purcell, Hung made the natural progression into music videos including one he made for Enfield, N.S.'s Classified featuringSnoop Dog.

For Hung, 31, he's proven that you can soar to great heights in the air, and in life, through skateboarding.

"Learning how to do things like land a kick-flip for the first time. It's a clear goal that you have in mind, and the nuances of how to move your feet and when to jump is just so convoluted at first that it takes thousands and thousands of tries," he said.

"Not only is it the most gratifying sort of feeling, it's just a great marker of success. And I feel like getting to the point where you can get into medical school, matched to the residency program that you're interested in, is a lot of that," said Hung.

The skateboard park is conveniently located across the street from the emergency department at the QEII Health Sciences Centrewhere he'll work occasionally alongside his dad, Dr. Orlando Hung, an anesthesiologist.

He and his dad, along with his brother, Chris, who's also in medical school, recently collaborated with Dr. Ron Stewart, a former Nova Scotia health minister, on a paper for the Canadian Journal of Anesthesia about reducing the risk of catching COVID-19 when removing a breathing tube from patients.

Hung turned on the camera to shoot and edit a video to accompany the academic paper.

"It's on YouTube. Check it out, don't check it out. It's super boring, you're going to hate it," he said with a big smile.

It couldn't be more different than his other works.

In the 2019 Netflix documentaryLook Mom I Can Flyabout rap star Travis Scott, Hung was on a team that captured Scott's wild concert energy.

In his Kylie Jenner commercial for Adidas, Hung combines the esthetic of blending new video with an old VHS-style look, a signature in his skate videos.

And while working on Kanye West's music videoFamoushe honed skills he'll need as a doctor.

"When you work with anybody at that level, it's a work environment that's full of incredibly high expectations. Sometimes what that can feel like is high stakes, high stress environments," he explained.

"Working for someone in the entertainment industry may not be necessarily like a life or death circumstance. You know, some people could view it as the life and death of the career. So I think there's a lot of parallels to draw."

Hung said he "tried not to go into medicine," but his roundabout career path still took him there.First he studied theatre, earning an arts degree at Dalhousie, before working as a paramedic in Nova Scotia for four years.

He enjoyed the energy of paramedicine and the flexibility it provided to work in film, but he craved more. His father's love of being a doctor, even after long days in the operating room, had him reconsidering his career.

"Seeing him beaming with a smile ear-to-ear every single day he went to work, I thought that was so rare and unique and inspiring," he said.

He's quick to credit his two best friends from Nova Scotia, director Tyler Ross and rapper Jacob Smith,who've helped him keep up his creative career while juggling medical school.

When Ross found work in California, he remained loyal to his friends byrecruiting them forprojects.

Hung remembered his friends in his valedictory speech, which he delivered last week in a virtual convocation ceremony, and said they are examples of going against the norm in society.

"I just hope that my story, if anything, inspires people to think that you don't just have to fit into one box or one category," he said. "I'm a firm believer that anything is possible if you have the drive and passion to pursue it."

Having landed an emergency medicine position in his hometown, he and his partner can raise their newborn daughter with family close by. Hung also intends to find time to keep up with creative projects.

He's still the film guy and the guy in medicine who's living his dream.

"If I can keep this up, everything will be just fine," said Hung.


Read the original:

From Hollywood to the hospital, a Halifax man's creative path to medicine - CBC.ca

How Coronavirus is Impacting Market Size of Nuclear Medicine & Radiopharmaceuticals , Forecast Report 2019-2027 – Cole of Duty

Nuclear Medicine & Radiopharmaceuticals Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Nuclear Medicine & Radiopharmaceuticals market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Nuclear Medicine & Radiopharmaceuticals is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Nuclear Medicine & Radiopharmaceuticals market was valued at USD _ million/billion.

This research report based on Nuclear Medicine & Radiopharmaceuticals market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Nuclear Medicine & Radiopharmaceuticals market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Nuclear Medicine & Radiopharmaceuticals industry.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2569264&source=atm

Nuclear Medicine & Radiopharmaceuticals Market Overview:

The Research projects that the Nuclear Medicine & Radiopharmaceuticals market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

The report on the Nuclear Medicine & Radiopharmaceuticals market provides a birds eye view of the current proceeding within the Nuclear Medicine & Radiopharmaceuticals market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Nuclear Medicine & Radiopharmaceuticals market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Nuclear Medicine & Radiopharmaceuticals market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading manufacturers of Nuclear Medicine & Radiopharmaceuticals Market:

The following manufacturers are covered:Bracco ImagingBayerMallinckrodtNordionTriad IsotopesLantheusIBA GroupGE HealthcareChina Isotope & RadiationJubilant PharmaEli LillyAdvanced Accelerator ApplicationsSIEMENSDongchengNavidea

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeDiagnostic RadioisotopesTherapeutic Radioisotopes

Segment by ApplicationOncologyCardiologyOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2569264&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2569264&licType=S&source=atm

The Questions Answered by Nuclear Medicine & Radiopharmaceuticals Market Report:

And Many More.

Read this article:

How Coronavirus is Impacting Market Size of Nuclear Medicine & Radiopharmaceuticals , Forecast Report 2019-2027 - Cole of Duty

‘Married to Medicine’: Britten dodges questions on intimacy issues with Mack, does she fear being judged? – MEAWW

As promised, 'Married to Medicine: Los Angeles' has started to test marriages and friendships but in a gradual manner. However, Shanique Drummond and Lia Dias's feud has reached a new, mind-numbing level. But that's not the only scoop of drama this Bravo show has to offer its viewers.

On paper, Britten Cole and husband Mack Major make for an ideal couple but off of it, their relationship isn't a bed of roses. And, the underlying cause could be intimacy issues.

Last week, Mack and Britten were spending their time having a conversation when their son, Mack Jr., jumped into the bed indicating that it was time for bed and for Mack to go into the other room and sleep.

During the green-room interview, Mack said how it bothered him that their son would sleep in his bed whereas he'd have to find a spot someplace else in the house. He wasn't direct but he did express a slight annoyance about not being able to sleep in the same bed with Britten.

He travels a lot, which means he's only around for two days a week. And to spend the limited time in separation would tick anyone off. However, Britten thinks of it as an adjustment they'd have to make because kids are used to having her around and therefore wish to sleep in the same bed as her when Mack is traveling.

Today, we see her friends confront her about the sleeping situation, to which she responded defensively. Britten shook her head and confirmed that she doesn't have intimacy issues with Mack.

Is she in denial or does she fear judgment?

Britten's good friend Imani Walker's husband, Phil Johnson, has been away for over three months. And she has had to explain herself a lot because of that. On and off, the ladies have speculated about what could have kept the couple (Imani-Phil) apart and most of the time, they've come up with just one guess - Phil may be over Imani.

This could be running through Britten's mind. The more people discuss, the more fodder they'll have for gossip and by the end of it all, she'll be explaining herself to everyone. Either this or maybe she is not prepared to accept the fact that the butterflies and sparkles have left their marriage.

But, these are mere shots in the dark because Britten hasn't directly addressed these issues on the show or off of it. In a chat with MEA WorldWide, Britten shared how difficult it had gotten to discuss her personal life on camera but she eventually managed.

"I think anytime you have cameras in front of you, whether your sharing something personal or you know being comedic or whatever it is, it's always kind of difficult to do that because you know someone's watching it's just hard in general, whatever you're doing it's hard to have a camera in front of you talking about things that are personal between my, my husband definitely was difficult but because it was real and it was personal," she had pointed out.

Catch all the new episodes of 'Married to Medicine: Los Angeles' on Bravo every Sunday.

Follow this link:

'Married to Medicine': Britten dodges questions on intimacy issues with Mack, does she fear being judged? - MEAWW

Hip Osteoarthritis Pain Medicine Market Research Size foreseen to grow exponentially over 2019 2025 – 3rd Watch News

The Hip Osteoarthritis Pain Medicine report provides independent information about the Hip Osteoarthritis Pain Medicine industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Hip Osteoarthritis Pain Medicine MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Hip Osteoarthritis Pain Medicine Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Hip Osteoarthritis Pain Medicine Market: Products in the Hip Osteoarthritis Pain Medicine classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Pfizer, Johnson& Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Novartis, Sanofi, Horizon Pharma, Abbott, Mylan, Daiichi Sankyo, TEVA, Almatica Pharma, Astellas Pharma, Tide Pharmaceutical, Iroko Pharmaceuticals, Hengrui Pharmaceutical, Abiogen Pharma

Hip Osteoarthritis Pain Medicine Market Report Covers the Following Segments:

Segment by Type:


Segment by Application:

Medical CarePersonal Care

North America



South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Hip Osteoarthritis Pain Medicine Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Hip Osteoarthritis Pain Medicine Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Hip Osteoarthritis Pain Medicine Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Hip Osteoarthritis Pain Medicine Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Hip Osteoarthritis Pain Medicine Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Hip Osteoarthritis Pain Medicine Market.

Market Forecast:Here, the report offers a complete forecast of the global Hip Osteoarthritis Pain Medicine Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read more:

Hip Osteoarthritis Pain Medicine Market Research Size foreseen to grow exponentially over 2019 2025 - 3rd Watch News

There are few certainties in coronavirus medicine research is our best weapon – The Guardian

This pandemic is frightening for many people especially those at the highest risk and the need for effective prevention and treatment is pressing.

When there is no direct evidence about what is best to do with a new disease, we need to create it. Clearly, that means recognising that some seemingly sensible interventions may not produce the intended effects. All of medicine is a bit uncertain (unlike maths, where proof is immutable). We can be very certain about some things (drinking bleach is harmful) and less certain about others (could vitamin D be useful?) Admitting uncertainty is something medicine historically finds difficult. But if we dont recognise the gaps in our knowledge, we wont research them. And good research has to be the way out of this.

There are now thousands of research papers on Covid-19, but many of such poor quality that we shouldnt rely on them. This means extra care and critique is needed. And on that basis, we simply dont know if vitamin D, for example, will help with Covid-19 (although all UK residents get a recommendation either to take or consider taking vitamin D the evidence for benefit is either absent or small with the exception of asthma). To know if it will help against Covid-19 needs rapid research for instance, assessing the vitamin D levels of people with severe Covid-19 against similar people who have less severe Covid-19 or avoid getting it altogether, or asking a group of people at high risk to diligently take supplements, and monitoring what happens.

As far as hydroxychloroquine goes, initial trials of this drug which is typically used to prevent malaria (and has been promoted by Donald Trump as a possible cure for all things Covid-19) were initially of poor quality, tiny, and with no control groups. Yet they were widely reported as showing it helped, while better quality trials that followed showed it didnt. Research is now focused on whether it might work as a preventive measure. Knowing what doesnt work is vital. It means that we can stop wasting resources on things that dont work and avoid unnecessary side-effects. Its also clear that hydroxychloroquine has cardiac side-effects, a fact that needs care in monitoring. There is no such thing as an intervention that is free of side-effects.

This doesnt just go for drug treatments. It should hold true for non-drug treatments. There is a clamour for everyone in public to wear a face covering. Does it work? Some research papers insist it does offering reasons as to why fabric will stop the passage of viral particles from the mouth and nose. But what really matters is whether this would result in fewer people being infected. So far, three reviews of the evidence (which have yet to be peer-reviewed) have found no or slender evidence, at best, for any benefit. But a bigger concern is a lack of investigation of unintended consequences. Would people wearing face coverings manage not to touch their faces or would they subconsciously take risks, which results in more infections, not fewer? What does this mean for deaf or lipreading people, or those with cognitive difficulties? Hazards for some may be accepted if there are outweighing benefits for everyone but, when the evidence is so slender, we need rational deliberation.

Would policymakers assume face coverings work, and make decisions on, for instance, encouraging the use of public transport on this basis without high-quality evidence to tell us this is safe? The truth is that we dont know, because we dont have the studies. The counter-argument is its a global pandemic, we cant wait for the results of research. I would argue that because it is a global pandemic, we need good, rapid research even more: the results will be applicable to far more people than usual when a drug or potential preventive measure is tested, hence the need to get better evidence for everyone. And yes, the need is urgent but this pandemic has no clear end in sight.

We could do fast, pragmatic, real-world studies, supplying masks to a geographical area with encouragement and instruction on use, and monitor for comparative changes in infection rates, together with carrying out field studies to observe peoples behaviour. Difficult, yes; but impossible, no. The World Health Organization has made it clear that we need research during pandemics (and drug trials have got off to an amazingly fast start), but this needs to hold true for things like face coverings too. What seems a sensible and obvious solution may not be. Harms and unintended consequences are everywhere, but are only reckoned with properly if we look for them.

Medicine is now in the era of Covid-19. This could be a turning point: where we take the uncertainty we are facing and, rather than assuming that our interventions will work, everyone citizens, patients, researchers and healthcare staff comes together to reduce it.

Margaret McCartney is a GP who writes about evidence-based medicine; she is the author of The State of Medicine: keeping the promise of the NHS

Read more:

There are few certainties in coronavirus medicine research is our best weapon - The Guardian

AIIMS former head of medicine dept dies of COVID – The Tribune India

Tribune News Service

New Delhi, May 23

Dr Jitendra Nath Pande, an acclaimed medical specialist and former head of the Department of Medicine at the All India Institute of Medical Sciences (AIIMS), New Delhi, died at his residence on Saturday.

Dr Jitendra Nath Pande was 79.

He was serving as a consultant at a Delhi-based private hospital after retiring from the AIIMS. His wife is also currently hospitalised with the infection.

Dr Jitendra Nath Pande had tested positive for COVID-19 earlier this week.

Dr Pande and his wife tested positive for COVID-19 on Tuesday with mild symptoms and had decided to remain in home isolation, said AIIMS director Dr Randeep Guleria.

But his wife was shifted to the AIIMS on Saturday.

We were following up on him regularly and he said he was improving. Yesterday, after having his dinner, he went off to sleep and then passed away in his sleep possibly because of an acute cardiac event, Dr Guleria said.

Dr Pande had co-morbid conditions.

Knowledge and humility can co-exist and Dr Pande was an epitome of that. He was an excellent human being and it is a great loss to the medical fraternity. AIIMS family will miss him the most because he joined AIIMS as an MBBS student and retired as the head of the Department of Medicine, Dr Guleria said.

I have closely worked with him and knew him since my childhood as he was the student of my father, he added.

After his retirement in 2003, Dr Pande joined the Sitaram Bhartia Institute of Science and Research and worked there as a senior consultant in the Respiratory Medicine Department.

He was a legendary physician who had taught many practising doctors at AIIMS and continued to mentor physicians even after joining this hospital. What was remarkable was that most difficult cases would come to him, said the institutes director, Abhishek Bhartia.

I even spoke to him yesterday. He was under home care and seemed to be recovering.

Sangita Reddy, joint managing director, Apollo Hospitals Group, and president of industry chamber FICCI, said in a tweet: Deeply saddened to hear that today. @covid19 claimed its most illustrious victim Dr JN Pande Director & Prof of Pulmonology @aiims_newdelhi. A stalwart of the medical world his work in pulmonology will continue to ensure better health for many. My Condolences to his family. With agency inputs

Read more from the original source:

AIIMS former head of medicine dept dies of COVID - The Tribune India

My Turn: It’s time to take our medicine – Concord Monitor

Published: 5/22/2020 6:20:14 AM

Modified: 5/22/2020 6:20:03 AM

This past weekend offered a snapshot of where we are in the pandemic. On Saturday, there were protests at the State House.

The group ReOpenNH led the display with both the protests (no masks, no social distancing) and a coordinated op-ed piece in local papers.

Meanwhile, there were 13 more COVID-19 deaths in New Hampshire and the Strafford County jail reported its first two cases of COVID-19: one staff member and one ICE detainee.

In his opinion, Mr. Manuse, the chair of ReOpenNH, feels the restrictions have been an unnecessary intrusion upon our liberties and this entire pandemic is some sort of political ploy. He states that according to New Hampshire statistics, were more likely to die from an opioid overdose than from COVID-19. He further states that people under the age of 15 are more likely to die from the flu.

Of course, the reality is much more complicated and different from Mr. Manuses beliefs. Anyone can be a viral vector and spread the disease whether or not they experience symptoms. The virus will spread to our most vulnerable through contact with his or her younger loved ones.

He also ignores the fact that the only people who die from an opioid overdose are those who use them recreationally. No one gets COVID-19 intentionally.

The youth in New Hampshire are no different biologically than the youth in Massachusetts or New York. Thats where a mysterious offshoot of COVID-19, called Multisystem Inflammatory Syndrome in Children is killing some children and hospitalizing about 200 other in the United States alone. So if the disease doesnt prove fatal to our children, the hospital bill might be fatal to the parents.

We need to listen to our doctors advice. They dont get paid for preaching a political agenda and they dont want to prolong their own lockdown restrictions any more than the rest of us.

Our health and our economy are sick, but if we all just take our medicine we will all be back on our feet again.

(Dr. James Fieseher lives in Dover.)

Go here to see the original:

My Turn: It's time to take our medicine - Concord Monitor